OpenURL Connection Search

Select item for more details and to access through your institution.

Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.
Published in:
Neuro-Oncology Advances, 2022, v. 4, n. 1, p. 1, doi. 10.1093/noajnl/vdac143
By:
- Gardner, Sharon L.;
- Tarapore, Rohinton S.;
- Allen, Jeffrey;
- McGovern, Susan L.;
- Zaky, Wafik;
- Odia, Yazmin;
- Daghistani, Doured;
- Diaz, Zuanel;
- Hall, Matthew D.;
- Khatib, Ziad;
- Koschmann, Carl;
- Cantor, Evan;
- Ryo Kurokawa;
- MacDonald, Tobey J.;
- Aguilera, Dolly;
- Vitanza, Nicholas A.;
- Mueller, Sabine;
- Kline, Cassie;
- Guangrong Lu;
- Allen, Joshua E.
Publication type:
Article
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Published in:
Journal of Neuro-Oncology, 2019, v. 145, n. 1, p. 97, doi. 10.1007/s11060-019-03271-3
By:
- Chi, Andrew S.;
- Tarapore, Rohinton S.;
- Hall, Matthew D.;
- Shonka, Nicole;
- Gardner, Sharon;
- Umemura, Yoshie;
- Sumrall, Ashley;
- Khatib, Ziad;
- Mueller, Sabine;
- Kline, Cassie;
- Zaky, Wafik;
- Khatua, Soumen;
- Weathers, Shiao-Pei;
- Odia, Yazmin;
- Niazi, Toba N.;
- Daghistani, Doured;
- Cherrick, Irene;
- Korones, David;
- Karajannis, Matthias A.;
- Kong, Xiao-Tang
Publication type:
Article
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Published in:
Neuro-Oncology, 2024, v. 26, p. S165, doi. 10.1093/neuonc/noae021
By:
- Odia, Yazmin;
- Hall, Matthew D;
- Cloughesy, Timothy Francis;
- Wen, Patrick Y;
- Arrillaga-Romany, Isabel;
- Daghistani, Doured;
- Mehta, Minesh P;
- Tarapore, Rohinton S;
- Ramage, Samuel C;
- Allen, Joshua E
Publication type:
Article
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
Published in:
Neuro-Oncology, 2024, v. 26, p. S155, doi. 10.1093/neuonc/noae001
By:
- Odia, Yazmin;
- Koschmann, Carl;
- Vitanza, Nicholas A;
- Blank, Peter de;
- Aguilera, Dolly;
- Allen, Jeffrey;
- Daghistani, Doured;
- Hall, Matthew;
- Khatib, Ziad;
- Kline, Cassie;
- MacDonald, Tobey;
- Mueller, Sabine;
- Faison, Shamia L;
- Allen, Joshua E;
- Naderer, Odin J;
- Ramage, Samuel C;
- Tarapore, Rohinton S;
- McGovern, Susan Lynne;
- Khatua, Soumen;
- Zaky, Wafik
Publication type:
Article
First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.
Published in:
Journal of Neurosurgery, 2019, v. 23, n. 6, p. 719, doi. 10.3171/2019.2.PEDS18480
By:
- Hall, Matthew D.;
- Odia, Yazmin;
- Allen, Joshua E.;
- Tarapore, Rohinton;
- Khatib, Ziad;
- Niazi, Toba N.;
- Daghistani, Doured;
- Schalop, Lee;
- Chi, Andrew S.;
- Oster, Wolfgang;
- Mehta, Minesh P.
Publication type:
Article

Found: 5

Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.

Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.

First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.